Search
Precipio Inc
PRPOAdd to Watchlist
26.040USD
-2.560-8.95%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
46.45MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-8.95%
5 Days
-12.65%
1 Month
-10.21%
6 Months
+34.71%
Year to Date
+13.32%
1 Year
+230.46%
TradingKey Stock Score of Precipio Inc
Currency: USD Updated: 2026-05-15Key Insights
Precipio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 155 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precipio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Precipio Inc Highlights
StrengthsRisks
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.25% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.05M.
Undervalued
The company’s latest PE is -58.14, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 341.74K shares, decreasing 7.77% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 14.50K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.65.
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Precipio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Precipio Inc Info
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Ticker SymbolPRPO
CompanyPrecipio Inc
CEODanieli (Ilan S)
Websitehttps://www.precipiodx.com/
Related Instruments
-1.32%
-2.23%
-1.62%
-0.49%
-1.30%
+0.41%
-1.57%
-2.22%
-1.05%
-1.04%
-1.59%
-3.29%
-1.06%
+0.04%
-0.76%
-0.71%
+1.31%
-1.21%
-1.39%
-0.56%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
77774.450
-456.550 (-0.58%)
422.240
-21.060 (-4.75%)
